THAILAND · MALAYSIA · MEDICAL DEVICES
Thai FDA Recognises Malaysia MDA: Eligibility and Document Checklist
Since 6 October 2026, Malaysia’s Medical Device Authority (MDA) has been on the Thai FDA list of recognised foreign agencies. For manufacturers with a Malaysian approval who plan to enter Thailand, the practical opportunity is this: an application that meets the MDA–Thai FDA reliance programme conditions can skip the external expert evaluation, but must still be filed in Thailand with a Full CSDT.
Whether the route is open depends on three things: the evaluation basis behind the Malaysian approval, whether the product to be sold in Thailand matches the approved Malaysian version, and whether the complete technical file can be obtained and used for the Thai application. This article works through each question for manufacturers and local applicants preparing a project. (Sources: Thai FDA list of recognised foreign agencies (No. 2); MDA–Thai FDA joint announcement)
What did the notification change? Three dates to keep apart
The MDA–Thai FDA Medical Device Regulatory Reliance Programme lets each regulator rely on the other’s completed review work. The October 2026 Thai notification is a separate step from the earlier pilot and the full launch.
| Date | Official step | What it means for manufacturers |
|---|---|---|
| 1 February – 30 April 2026 | Bilateral pilot (announced when the confidentiality agreement was signed on 4 December 2025) | The pilot name still appears on some guidance pages and in system options. |
| 1 May 2026 | Joint announcement of full implementation | Covers both directions: no external expert evaluation in Thailand; the Verification Route in Malaysia. |
| 6 October 2026 | MDA added to the Thai list of recognised agencies | Eligibility must be checked against both conditions in new annex item 8. |
The Thai notification was signed and took effect on 6 October; 8 October is the date it was posted on the website. The joint announcement lists Class B, C and D, and the Thai FDA programme page limits the route to risk classes 2 to 4 (Class B to D). The product must still be classified under Thai rules rather than converting the Malaysian class directly; Class 1 products follow their own procedure. (Sources: notification page; Thai FDA programme conditions)
Already registered with MDA? Check these three things first
1. Confirm the evaluation basis behind the approval
Paragraph (1) of new annex item 8 requires that the device has been approved or registered by MDA, falls within the scope of the MDA–Thai FDA reliance programme, and was not approved in a form exempted from MDA’s safety and performance evaluation. The Thai FDA programme page gives Class A and Exempted product approval as examples of what is excluded, and also excludes devices covered by a specific Thai notification. For an existing MDA registration, review both the certificate and the assessment records behind it to confirm they can support the Thai application. (Source: notification text, annex item 8(1))
If the device was registered in Malaysia through the Verification route, check the reference approval, the CAB assessment records and the scope of the MDA approval together. The route name “Verification” on its own neither establishes eligibility nor rules it out. For background on Malaysian routes, see Malaysia MDA medical device registration.
2. Match the Thai product to the Malaysian approved version
What needs comparing is the actual product scope. The same trade name does not mean the same models, use, user population or label claims. Build a version-difference table first, then decide which application route to use.
| Check | Documents to compare | Differences to resolve first |
|---|---|---|
| Product identity | MDA certificate, approved trade name, models and product codes | Are all models planned for Thailand within the approval? Any new sizes or configurations? |
| Use and indication | Approved intended use, indication and IFU | Any added diseases, analytes, clinical uses or new patient populations? |
| Conditions of use | IFU, performance data and proposed Thai instructions | Any change between professional and self-test use, specimen type or setting? |
| Labelling and packaging | Approved label, IFU and packaging versions versus proposed versions | Are brand, claims, models and versions consistent? How are local-language differences handled? |
Identical intended use, indication, labelling, IFU and packaging is required by paragraph (2) of annex item 8; identical trade name, model and product code is stated on the Thai FDA programme page. The “conditions of use” row is a practical recommendation for preparing the difference table. New Thai-language labels or translations should also be checked line by line rather than assumed not to affect consistency. (Sources: notification text, item 8(2); Thai FDA programme conditions)
Illustrative scenario: a reagent is approved in Malaysia for professional use, and the manufacturer wants to add self-test use in Thailand. Even with the same reagent name, manufacturer and technology platform, the use and intended user have changed, so the effect on eligibility must be confirmed before filing. This scenario illustrates the method and is not an approved case.
3. Confirm the complete file can be obtained and used in Thailand
Thai FDA requires the same Full CSDT used for the Malaysian registration, together with evidence of the Malaysian registration. Agree early which documents the manufacturer, the Malaysian AR and the Thai applicant each hold, and who has the right to provide and use them. (Sources: programme documents; official filing steps)
Once these checks are done, plan the next step by outcome. This is project-planning advice and does not replace the regulator’s decision on eligibility.
| Outcome of the checks | Suggested next step |
|---|---|
| Approval basis is clear, documents are available, product scope matches | Confirm eligibility for the reliance route and arrange the Thai applicant and dossier in parallel. |
| Assessment basis is unclear, or models, use or document versions differ | Obtain the approval and assessment records, document the differences, then confirm whether the route can be used. |
| Confirmed not eligible | Compare the other Thai application routes and re-plan documents, cost and launch timing. |
A Full CSDT is still required: what to prepare before you start
The checklist below is MediPass’s recommended project start-up list for collecting existing evidence, identifying gaps and planning delivery. The actual submission set should be confirmed against the programme conditions and current system requirements.
| Package | Suggested provider | What to check before starting |
|---|---|---|
| MDA approval and product scope | Malaysian registration holder / AR | Certificate, model annex, approval scope and related change records. |
| Assessment records behind the approval | Manufacturer, AR and the relevant CAB | Available assessment reports, conformity certificates and reference approvals; confirm the evaluation basis. |
| Complete technical file | Manufacturer / Product Owner | CSDT for the approved version, performance and clinical evidence, risk management and applicable quality documents. |
| Version differences and delivery | Manufacturer and applicants in both countries | Malaysian approved version, Thai proposed version, document numbers, and rights to provide and use them. |
When filing in Thai E-submission, the official steps require a Full CSDT; on the application page select “the application is in the Reliance program”, then the MDA project, and accept the declaration; the Malaysian registration evidence goes into the Executive Summary. The option currently still reads “Malaysia MDA – Thai FDA Pilot Project”, so follow the system option shown at the time of filing. (Source: official filing steps)
For the Thai local applicant, risk classification and the different application procedures, see Thailand medical device registration.
How should IVDs and self-test products be assessed?
The Thai FDA programme conditions exclude devices covered by a specific Thai notification, and such product-specific rules change over time: on 14 August 2024, for example, Thailand’s Ministry of Public Health revoked six notifications on SARS-CoV-2 test kits and moved them to risk-based control. For IVDs and self-test devices, check the current product-specific requirements and programme exclusions for the particular device, including its analytes, specimen type, intended users and approved scope in each country, then confirm risk class, grouping and route separately. One eligible product does not make every test combination under the same brand eligible. (Source: Thai FDA, COVID-19 test kit control update)
Is it worth registering in Malaysia first, then Thailand?
That depends on the sales plan in both countries and the approvals already held. The scenarios below are planning advice, not a commitment on timing or cost by any regulator.
Already registered with MDA, same product version. Assess the reliance route first, focusing on the approval basis, document availability and the Thai applicant.
Not registered in either country, and the Thai launch is urgent. Compare a direct Thai application, parallel preparation in both countries and Malaysia-then-Thailand in one plan. The time and cost of a new Malaysian registration must be counted in the total, not just the evaluation step that may be saved in Thailand.
Already registered in Thailand and changing the local licence holder. Start with Thailand medical device licence transfer. Cross-border reliance and transferring an existing Thai registration solve different problems.
Frequently asked questions
Can I sell in Thailand once I hold an MDA registration?
No. A Thai product application is still required, and a Thai licence holder carries the registration and import responsibilities. The MDA registration and assessment evidence support eligibility for the route and the Thai review.
Which evaluation does this route save?
The 1 May joint announcement states that, where eligible, the Thai side can skip the external expert evaluation, with a Full CSDT still submitted. It does not follow that other documents, official checks or applicable requirements are waived. (Source: full implementation announcement)
Can every MDA registration obtained through Verification use this route?
It has to be assessed case by case: check the original assessment basis, the reference approval and whether the approval was granted in a form exempted from safety and performance evaluation. The public material does not support accepting or excluding them across the board.
The Thai models, IFU or packaging differ. How should we prepare?
Build a line-by-line difference table between the Malaysian approved version and the proposed Thai version. Where use, test configuration or conditions of use change, confirm first whether the route conditions are still met; making two documents read the same does not solve a real difference in product scope.
Does it work the other way, from a Thai registration to Malaysia?
The joint announcement also states that devices approved by Thai FDA can apply in Malaysia through the MDA Verification Route (MDA/GD/0070) instead of the full evaluation route; reference-approval and CAB verification requirements follow the MDA guidance. See Malaysia MDA medical device registration.
How long does the route take, and is it cheaper?
The official documents reviewed do not give a route-specific timeline or fee that can be applied generally. When comparing options, include any new Malaysian registration cost, Thai application fees, document completion and translation, and applicable third-party fees, then plan time for preparation, eligibility confirmation, submission and queries.
Official references
- Thai FDA Medical Device Control Division, Notification of the Office of the Food and Drug Administration on the list of foreign agencies whose inspection or certification of medical devices or establishments is recognised (No. 2) B.E. 2569, signed and effective 6 October 2026, https://medical.fda.moph.go.th/relevant-laws-and-standards/mdlaw0510
- Notification text (PDF), new annex item 8(1) approval basis and exclusions, 8(2) product consistency, https://medical.fda.moph.go.th/media.php?id=948770118886891520&name=mdlaw0510.pdf
- MDA and Thai FDA, Joint Announcement: Full Implementation of the MDA – Thai FDA Medical Device Regulatory Reliance Programme, 1 May 2026, https://portal.mda.gov.my/index.php/ms/pengumuman/1795-…-on-1-may-2026
- Thai FDA Medical Device Control Division, Malaysia MDA – Thai FDA programme conditions and required documents, https://medical.fda.moph.go.th/international-cooperation/mda-thfda-description-detail/
- Thai FDA Medical Device Control Division, programme filing steps (E-submission), https://medical.fda.moph.go.th/international-cooperation/mda-thfda-process-detail
- Thai FDA Medical Device Control Division, Ministry of Public Health notifications adjusting the control of COVID-19 test kits by risk (six SARS-CoV-2 test kit notifications revoked on 14 August 2024), 6 September 2024, https://medical.fda.moph.go.th/relevant-laws-and-standards/newscovid19/
Prepared from official sources verifiable as of 8 October 2026 for general compliance planning; applicability must be confirmed against the product, the original approval basis, the proposed scope and the regulator’s requirements.
